Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16518358 | 0.85 | MAPK1 (0.43) | NPC1SMN1; SMN2LMNARAB9AALDH1A1 | |
| SCHEMBL11455772 | 0.85 | CSNK2A1 (0.43) | NPC1LMNARAB9AALDH1A1PDE4B | |
| SCHEMBL12831493 | 0.82 | PTPN1 (0.39) | NPC1RAB9AMEN1KMT2APTPN1 | |
| SCHEMBL7161254 | 0.82 | PTPN1 (0.41) | SMN1; SMN2MEN1KMT2APTPN1PDE4B | |
| SCHEMBL1423552 | 0.82 | PTPN1 (0.39) | NPC1SMN1; SMN2RAB9AALDH1A1KDM4E | |
| SCHEMBL1423603 | 0.82 | L3MBTL1 (0.42) | NPC1RAB9AMEN1KMT2APTPN1 | |
| SCHEMBL13478345 | 0.82 | TSHR (0.38) | ALDH1A1PDE4B | |
| SCHEMBL7242085 | 0.81 | NPC1 (0.46) | NPC1RAB9APTPN1PDE4B | |
| SCHEMBL16518352 | 0.80 | ALDH1A1 (0.44) | NPC1SMN1; SMN2LMNARAB9AALDH1A1 | |
| SCHEMBL11463272 | 0.80 | HPGD (0.44) | SMN1; SMN2LMNAALDH1A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| CN-102131798-A | Di-substituted phenyl compounds used as inhibitors of phosphodiesterase 10 | ENVIVO PHARMACEUTICALS INC | 2011-07-20 | — | — | CN | disclosed |
| EP-2297131-A2 | DI-SUBSTITUTED PHENYL COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Envivo Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009158467-A2 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | PDE10A, PDE1A, PDE12 | NPC1 2142/4885SMN1; SMN2 324/4885LMNA 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.